Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Castanospermine SCHEMBL29356587 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL10471084 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL30094437 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL31666834 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL23845877 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL2434193 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL23689596 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL764545 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL13666292 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL2267745 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1387681-B1 | USE OF CASTANOSPERMINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | VIROGEN LTD (GB) | 2008-08-20 | — | — | EP | claimed |
| EP-0297534-B1 | Castanospermine esters and glycosides | MERRELL DOW PHARMA (US) | 1994-12-28 | — | — | EP | claimed |
| EP-0412487-B1 | Process for the preparation of castanospermine esters | MERRELL DOW PHARMA (US) | 1994-12-28 | — | — | EP | claimed |
| EP-0309952-B1 | Anti-retroviral castanospermine esters | MERRELL DOW PHARMA (US) | 1994-06-22 | — | — | EP | claimed |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2016110702-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | ISIS INNOVATION LIMITED (GB) | 2016-07-14 | — | — | WO | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| EP-0297534-B1 | Castanospermine esters and glycosides | MERRELL DOW PHARMA (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0309952-B1 | Anti-retroviral castanospermine esters | MERRELL DOW PHARMA (US) | 1994-06-22 | — | — | EP | disclosed |
| EP-0492841-A1 | Anti-herpes castanospermine esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-5079254-A | DERIVATIVES OF 6-AMINOOCTAHYDROINDOLIZINETRIOL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0449294-A1 | Hydroxymethyl-indolizidines and quinolizidines | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5004746-A | Anti-retroviral castanospermine esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-02 | — | — | US | disclosed |
| US-4970317-A | Process for the preparation of castanospermine esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4952585-A | Castanospermine esters in the inhibition of tumor metastasis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | UGCG, SMPD1, SMPD4 | GAA 52/4885MEN1 3887/4885CYP1A2 1038/4885 |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CMA1, MAN2B1, GBA3 | GAA 13/4885MEN1 1633/4885CYP1A2 986/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | GAA 11/4885MEN1 2550/4885CYP1A2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.